Kiora Pharmaceuticals, Inc. (KPRX) Stock Score, Valuation & Financial Research

Kiora Pharmaceuticals, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for KPRX

Kiora Pharmaceuticals, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 2.50. These figures are a research snapshot, not a buy or sell recommendation.

What Kiora Pharmaceuticals, Inc. does

Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Kiora Pharmaceuticals is a clinical-stage specialty pharmaceutical company that generates revenue primarily through collaboration and licensing agreements related to its proprietary drug development programs. As a clinical-stage entity, it does not currently have commercialized products and relies on capital raises and strategic partnerships to fund its research and development activities for retinal disease therapies.

Products and services

The company is developing KIO-301, a molecular photoswitch for retinitis pigmentosa and other retinal diseases, and KIO-104, a non-steroidal, immuno-modulatory small molecule for retinal inflammation.

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

Contract Research Organizations (CROs) — The company relies on third-party contract research organizations to conduct its clinical trials and preclinical studies. Source
Contract Manufacturing Organizations (CMOs) — The company utilizes third-party contract manufacturing organizations for the production of its drug candidates for clinical use. Source

Business strengths to evaluate

Proprietary pipeline of clinical-stage retinal disease therapies Source

Business risks and research considerations

History of operating losses and dependence on additional financing Source
Clinical trial failure or delays Source
Regulatory approval uncertainties Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

KPRX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 2.50
Market capitalization:: 11.08M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -10.99M
Free cash flow:: USD -10.07M
Cash:: USD 7.08M
Total debt:: USD 333.02K
EPS:: USD -2.50

What stands out

Free cash flow is USD -10.07M, negative for the stored period.
The balance sheet shows USD 7.08M of cash versus USD 333.02K of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 6.74M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for KPRX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

How long can KPRX fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is KPRX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for KPRX to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of KPRX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research KPRX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.